Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Baltruškevičienė, Edita, Mickys, Ugnius, Žvirblis, Tadas, Stulpinas, Rokas, Pipirienė Želvienė, Teresė, Aleknavičius, Eduardas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lithuanian Academy of Sciences Publishers 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924637/
https://www.ncbi.nlm.nih.gov/pubmed/28356789
http://dx.doi.org/10.6001/actamedica.v23i1.3267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924637/
https://www.ncbi.nlm.nih.gov/pubmed/28356789
http://dx.doi.org/10.6001/actamedica.v23i1.3267

Ejemplares similares